Improvement in immune dysfunction after FOLFOX chemotherapy for Stage III colon cancer is associated with improved minimal residual disease prognostic subtype and outcome

Vista sencilla de ítem
dc.contributor.authorMurray, Nigel P.
dc.contributor.authorVillalon, Ricardo
dc.contributor.authorHartmann, Dan
dc.contributor.authorRodriguez, Maria Patricia
dc.contributor.authorAedo, Socrates
dc.date.accessioned2021-12-17T14:16:29Z
dc.date.available2021-12-17T14:16:29Z
dc.date.issued2021-08-24
dc.description.abstractAim: Minimal residual disease (MRD) is the net result of the biological properties of disseminated tumour cells and the effect of the immune system and treatment to eliminate them. The aim of this work is to report the changes in MRD status and immune function (lymphocyte count) after FOLFOX chemotherapy, and the outcome in Stage III colon cancer patients. Method: This study is a prospective, single-centre observational study. Lymphocyte counts were determined prior to and 1, 2 and 3 months after the completion of chemotherapy. Circulating tumour cells (CTCs) and bone marrow micrometastases were determined using immunocytochemistry with anticarcinoembryonic antigen prior to and 1 month after chemotherapy. MRD was classified as negative (Group I), micrometastasis positive only (Group II) and CTC positive (Group III). Changes in lymphocyte counts and MRD subtype following chemotherapy and relapse-free progression were analysed. Results: Of the total of 185 patients, 83 (44.9%) relapsed. The risk of relapse significantly increased from Groups I to III (p < 0.001) and with decreasing lymphocyte count (p < 0.01). The lymphocyte count significantly decreased from Groups I to III (p < 0.001). Multivariance Cox regression analysis showed hazard ratios of 3.58 (Group II), 17.43 (Group III) and 0.39 (lymphocyte count) in predicting relapse. Following chemotherapy, improved lymphocyte count was associated with improved MRD subtype (p < 0.0001). Neither baseline lymphocyte count nor MRD subtype predicted response to chemotherapy. Five-year relapse-free survival for combined lymphocyte–MRD subtypes was 95%, 57% and 5% for Groups I to III, respectively (p < 0.001). Conclusion: Following chemotherapy, improvements in immune function were associated with improved MRD subtype and a better relapse-free survival.es
dc.identifier.citationMurray NP, Villalon R, Hartmann D, Rodriguez MP, Aedo S. Improvement in immune dysfunction after FOLFOX chemotherapy for Stage III colon cancer is associated with improved minimal residual disease prognostic subtype and outcome. Colorectal Dis. 2021;00:1–15. https:// doi.org/10.1111/codi.15899es
dc.identifier.issn1463-1318
dc.identifier.orcidhttps://orcid.org/0000-0001-8154-8550es
dc.identifier.orcidhttps://orcid.org/0000-0002-8341-7658es
dc.identifier.orcidhttps://orcid.org/0000-0002-7140-4294es
dc.identifier.orcidhttps://orcid.org/0000-0001-6999-4099es
dc.identifier.orcidhttps://orcid.org/0000-0001-5567-3374es
dc.identifier.orcidhttps://doi.org/10.1111/codi.15899
dc.identifier.urihttp://hdl.handle.net/20.500.12254/2157
dc.language.isoenes
dc.publisherWileyes
dc.relation.ispartofseriesColorectal Disease;
dc.rightsAtribución-NoComercial-CompartirIgual 3.0 Chile (CC BY-NC-SA 3.0 CL)
dc.rights
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/cl/
dc.subject.otherChemotherapyes
dc.subject.otherColon canceres
dc.subject.otherImmune dysfunctiones
dc.subject.otherLymphocytopeniaes
dc.subject.otherMinimal residual diseasees
dc.titleImprovement in immune dysfunction after FOLFOX chemotherapy for Stage III colon cancer is associated with improved minimal residual disease prognostic subtype and outcomees
dc.typeArtículoes
dcterms.accessRightsEl artículo completo no puede ser publicado en el Repositorio Institucional debido a los permisos de copyright definidos por la editorial publicadora
Archivos
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
638 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
Artículos de Revistas